Mobile Site ›
Print Friendly View

Test ID: EPIES    
Epilepsy, Autoimmune Evaluation, Serum

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of <2 years

 

Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:

-Psychiatric accompaniments (psychosis, hallucinations)

-Movement disorder (myoclonus, tremor, dyskinesias)

-Headache

-Cognitive impairment/encephalopathy

-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency), or multiple sclerosis

-History of cancer         

-Smoking history (20+ pack years) or other cancer risk factors

-Investigating seizures occurring within the context of a subacute multifocal neurological disorder without obvious cause, especially in a patient with past or family history of cancer

-A rising autoantibody titer in a previously seropositive patient suggests cancer recurrence

Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test IDReporting NameAvailable SeparatelyAlways Performed
AEPSIEpilepsy, Interpretation, SNoYes
NMDCSNMDA-R Ab CBA, SNoYes
VGKCNeuronal (V-G) K+ Channel Ab, SNoYes
GD65SGAD65 Ab Assay, SYesYes
GABCSGABA-B-R Ab CBA, SNoYes
AMPCSAMPA-R Ab CBA, SNoYes
ANN1SAnti-Neuronal Nuclear Ab, Type 1NoYes
ANN2SAnti-Neuronal Nuclear Ab, Type 2NoYes
ANN3SAnti-Neuronal Nuclear Ab, Type 3NoYes
AGN1SAnti-Glial Nuclear Ab, Type 1NoYes
PCAB2Purkinje Cell Cytoplasmic Ab Type 2NoYes
PCATRPurkinje Cell Cytoplasmic Ab Type TrNoYes
AMPHSAmphiphysin Ab, SNoYes
CCNN-Type Calcium Channel AbNoYes
CCPQP/Q-Type Calcium Channel AbNoYes
ARBIACh Receptor (Muscle) Binding AbYesYes
GANGAChR Ganglionic Neuronal Ab, SNoYes
CRMSCRMP-5-IgG, SNoYes

Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
PCABPPurkinje Cell Cytoplasmic Ab Type 1NoNo
WBNParaneoplastic Autoantibody WBlot,SNoNo
CRMWSCRMP-5-IgG Western Blot, SNoNo
ABLOTAmphiphysin Western Blot, SNoNo
NMOCSNMO/AQP4-IgG CBA, SYesNo
NMDISNMDA-R Ab IF Titer Assay, SNoNo
AMPISAMPA-R Ab IF Titer Assay, SNoNo
GABISGABA-B-R Ab IF Titer Assay, SNoNo

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

If indirect immunofluorescence assay (IFA) patterns suggest PCA-1, then Purkinje cell cytoplasmic antibody type 1 is performed at an additional charge.

If IFA suggests ANN1S, ANN2S, ANN3S, PCAB2, PCATR, AMPHS, CRMS, AGN1S, or is indeterminate, then paraneoplastic autoantibody Western blot is performed at an additional charge.

If client requests, or if IFA patterns suggest CRMP-5-IgG, then CRMP-5-IgG Western blot is performed at an additional charge.

If IFA patterns suggest amphiphysin antibody, then amphiphysin Western blot is performed at an additional charge.

If IFA pattern suggest NMO/AQP4-IgG, then NMO/AQP4-IgG CBA is performed at an additional charge.

If IFA pattern suggest NMDA-R antibody and NMDA-R antibody CBA is positive, then NMDA-R titer is performed at an additional charge.

If IFA pattern suggest AMPA-R antibody and AMPA-R antibody CBA is positive, then AMPA-R titer is performed at an additional charge.

If IFA pattern suggest GABA-B-R antibody and GABA-B-R antibody CBA is positive, then GABA-B-R titer is performed at an additional charge.

 

Confirmation of GAD65 antibodies when IF screening suggests GAD65 antibodies.

 

Native neuronal antigens: performed to confirm neuronal nuclear and cytoplasmic Ab specificities when IF screening is uninterpretable.

 

Recombinant human collapsin response-mediator protein 5: performed to confirm CRMP 5-IgG when IF screening is uninterpretable. Also performed for more sensitive detection of CRMP 5-IgG.

 

See Epilepsy Autoimmune Evaluation Algorithm, Serum in Special Instructions

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

ANN1S, ANN2S, ANN3S, AGN1S, PCAB2, PCATR, AMPHS, CRMS, PCABP, NMDIS, AMPIS, GABIS: Indirect Immunofluorescence Assay (IFA)

VGKC, CCN, CCPQ, GANG, GD65S, ARBI: Radioimmunoassay (RIA)

WBN, CRMWS, ABLOT: Western Blot

AMPCS, GABCS, NMDCS: Cell Binding Assay (CBA)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Epilepsy-Autoimmune Evaluation, S

Aliases Lists additional common names for a test, as an aid in searching

Anti-Neuronal Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 2
Anti-Neuronal Nuclear Ab, Type 3
Anti-Glial Nuclear Ab, Type 1
Purkinje Cell Cytoplasmic Ab Type 2
Purkinje Cell Cytoplasmic Ab Type Tr
Amphiphysin Ab
CRMP-5-IgG
AMPA-R Ab CBA
GABA-B-R Ab CBA
NMDA-R Ab CBA
Glutamic Acid Decarboxylase (GAD65)
Neuronal (V-G) K+ Channel Ab
N-type Voltage-Gated Calcium Channel Ab
P/Q-type Voltage-Gated Calcium Channel Ab
ACh Receptor (Muscle) Binding Ab
AChR Ganglionic Ab
Seizures
Spells
EPIES_x